Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma

Author:

Figueirêdo Camila Bezerra Melo1,Souza Joelma Rodrigues de2,Soares Daniel Handerson Galindo3,Silva Caio Cesar de Andrade Rodrigues1,Lorena Virginia Maria Barros de4

Affiliation:

1. Federal University of Pernambuco, Brazil

2. Federal University of Paraíba, Brazil

3. Secretariat of Public Health of Sertânia, Brazil

4. Oswaldo Cruz Foundation, Brazil

Abstract

Non-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera(r)), which targets the CD20 protein, present in over 80% of NHL mature B cells. Recent clinical reports show a preference for combining the benefits of immunotherapy and adjuvant chemotherapy, thus generating safe and effective alternative treatments. The current review aimed at evaluating various aspects related to the use of rituximab for NHL, highlighting the possible inhibitory mechanisms of cell proliferation, the achieved clinical results, and the expected clinical and economic outcomes of treatments. The results from clinical tests indicate the need for a better understanding of the critical mechanisms of action of this antibody, which may maximize its therapeutic efficacy. This therapy not only represents a viable option to treat most types of NHLs, especially when associated with conventional chemotherapy, but also offers cost-utility and cost-effectiveness advantages.

Publisher

FapUNIFESP (SciELO)

Reference52 articles.

1. Regulação de mercado. Marcado de medicamentos,2013

2. Linfoma não-Hodgkin de alto grau - Revisão da literatura;ARAÚJO L.H.L.;Rev. Bras. Cancerologia,2008

3. Br. J. Haematol.;BARR P.M.,2009

4. Monoclonal antibodies for B cell lymphomas: rituximab and beyond;BELO C.;Hematology Am. Soc. Hematol. Educ. Program.,2007

5. Monoclonal antibodies;BISHOP M.R.,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3